menu
    • menu

    Company profile for Oxeia Biopharmaceuticals

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE-103, beginning a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients. The U.S. Centers for Disease Control and Prevention estimates that ...
    Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE-103, beginning a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients. The U.S. Centers for Disease Control and Prevention estimates that just under three million concussion cases visit U.S. emergency rooms annually. Other studies put the number much higher at five million, with as many as 2.4 million of these with mTBI.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oxeia BiopharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121-4361
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oxeiabiopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/oxeiabio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oxeia Unveils First Potential FDA-Approved Concussion Therapy
    Oxeia Unveils First Potential FDA-Approved Concussion Therapy

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oxeia-pioneering-first-potential-fda-approved-concussion-treatment-302654401.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Oxeia Announces Positive Interim Results Of Phase 2 Trial For Oxe103
    Oxeia Announces Positive Interim Results Of Phase 2 Trial For Oxe103

    03 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/03/2491668/0/en/OXEIA-ANNOUNCES-POSITIVE-INTERIM-RESULTS-OF-PHASE-2-TRIAL-FOR-OXE103-FOR-THE-TREATMENT-OF-CONCUSSIONS.html

    GLOBENEWSWIRE
    03 Aug 2022
    Share Share
    Oxeia announces new board, management members; relocates corporate headquarters
    Oxeia announces new board, management members; relocates corporate headquarters

    20 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/oxeia-biopharmaceuticals-announces-new-board-and-management-team-members-and-relocates-corporate-headquarters-to-boston-301464807.html

    PRNEWSWIRE
    20 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search